Enzo Biochem（EZB）株式概要ライフサイエンス企業であるエンゾ・バイオケム社は、DNAから全細胞分析までの標識・検出技術を米国内外で展開している。 詳細EZB ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金2/6報酬過去5年間の収益は年間0.6%増加しました。 リスク分析14.66%の配当は、利益やフリーキャッシュフローによって十分にカバーされていない 株式の流動性は非常に低い 意味のある時価総額がありません ( €30M )すべてのリスクチェックを見るEZB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW494,069 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG494,069 investors already sharing narrativesYour Fair Value€Current Price€0.3961.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-32m112m2016201920222025202620282031Revenue US$4.1mEarnings US$519.3kAdvancedSet Fair ValueView all narrativesEnzo Biochem, Inc. 競合他社PExASymbol: DB:FA0Market cap: €47.5mEvotecSymbol: XTRA:EVTMarket cap: €913.6mGerresheimerSymbol: XTRA:GXIMarket cap: €972.0mSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €2.6b価格と性能株価の高値、安値、推移の概要Enzo Biochem過去の株価現在の株価US$0.3952週高値US$1.0752週安値US$0.01ベータ1.171ヶ月の変化0%3ヶ月変化1.57%1年変化-62.69%3年間の変化-83.28%5年間の変化-80.40%IPOからの変化-99.41%最新ニュースお知らせ • Aug 29Enzo Biochem Appoints Jason Apter as Group CEOBattery Ventures announced the completion of its take-private of Enzo Biochem (Enzo). As part of this initiative, veteran life-science executive Jason Apter has joined Enzo as group CEO. Apter previously served as CEO of Sannova Analytical, an organization offering bioanalytical and analytical testing services to pharmaceutical and biotech companies. He also held senior leadership roles at MilliporeSigma and Johnson Matthey. Apter will be supported on Enzo’s board of directors by Battery’s Rosner, Feldman and Alan Hirzel, the former CEO of biological-reagents company Abcam.お知らせ • Aug 21Enzo Biochem, Inc. Files Form 15Enzo Biochem, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share.お知らせ • Aug 20Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB).Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. As of August 19 2025, the transaction was approved by target shareholders. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P. Equiniti Trust Company, LLC acted as Transfer agent to Enzo Biochem. Kingsdale Advisors LP acted as a proxy solicitor to Enzo Biochem. Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB) on August 20, 2025.お知らせ • Jun 26Enzo Biochem to Delist After Merger CompletionEnzo Biochem announced that on June 23, following the market close, it entered into an Agreement and Plan of Merger to be acquired by Battery Ventures, a technology-focused investment firm, through its newly formed entity Bethpage Parent. Under the terms of the merger agreement, Battery will acquire Enzo for 70c per share in cash, representing a total consideration of approximately $37 million. Following the closing of the transaction, the company will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges.お知らせ • Jun 25Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million.Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P.お知らせ • Jan 16Enzo Biochem Receives Non-Compliance Letter from NYSEOn January 8, 2025 Enzo Biochem, Inc. (the Company") received a letter from the New York Stock Exchange (the NYSE") notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company's 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Common Stock (the Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock from the NYSE. With regards to the average closing stock price deficiency, the Company can regain compliance at any time within the six-month period following receipt of the NYSE's non-compliance notice if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE's listing rules, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the following 30 consecutive trading days. The Company will notify the NYSE by January 23, 2025, that it intends to submit a plan by February 21, 2025, to cure the market capitalization, stockholder's equity and average closing stock price deficiencies and to return to compliance with the NYSE's continued listing standards. The Company intends to consider all available alternatives to cure the deficiencies identified by the NYSE. The Common Stock will continue to be listed and trade on the NYSE, subject to the Company's ongoing compliance with the NYSE's other continued listing standards.最新情報をもっと見るRecent updatesお知らせ • Aug 29Enzo Biochem Appoints Jason Apter as Group CEOBattery Ventures announced the completion of its take-private of Enzo Biochem (Enzo). As part of this initiative, veteran life-science executive Jason Apter has joined Enzo as group CEO. Apter previously served as CEO of Sannova Analytical, an organization offering bioanalytical and analytical testing services to pharmaceutical and biotech companies. He also held senior leadership roles at MilliporeSigma and Johnson Matthey. Apter will be supported on Enzo’s board of directors by Battery’s Rosner, Feldman and Alan Hirzel, the former CEO of biological-reagents company Abcam.お知らせ • Aug 21Enzo Biochem, Inc. Files Form 15Enzo Biochem, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share.お知らせ • Aug 20Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB).Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. As of August 19 2025, the transaction was approved by target shareholders. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P. Equiniti Trust Company, LLC acted as Transfer agent to Enzo Biochem. Kingsdale Advisors LP acted as a proxy solicitor to Enzo Biochem. Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB) on August 20, 2025.お知らせ • Jun 26Enzo Biochem to Delist After Merger CompletionEnzo Biochem announced that on June 23, following the market close, it entered into an Agreement and Plan of Merger to be acquired by Battery Ventures, a technology-focused investment firm, through its newly formed entity Bethpage Parent. Under the terms of the merger agreement, Battery will acquire Enzo for 70c per share in cash, representing a total consideration of approximately $37 million. Following the closing of the transaction, the company will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges.お知らせ • Jun 25Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million.Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P.お知らせ • Jan 16Enzo Biochem Receives Non-Compliance Letter from NYSEOn January 8, 2025 Enzo Biochem, Inc. (the Company") received a letter from the New York Stock Exchange (the NYSE") notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company's 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Common Stock (the Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock from the NYSE. With regards to the average closing stock price deficiency, the Company can regain compliance at any time within the six-month period following receipt of the NYSE's non-compliance notice if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE's listing rules, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the following 30 consecutive trading days. The Company will notify the NYSE by January 23, 2025, that it intends to submit a plan by February 21, 2025, to cure the market capitalization, stockholder's equity and average closing stock price deficiencies and to return to compliance with the NYSE's continued listing standards. The Company intends to consider all available alternatives to cure the deficiencies identified by the NYSE. The Common Stock will continue to be listed and trade on the NYSE, subject to the Company's ongoing compliance with the NYSE's other continued listing standards.お知らせ • Nov 28+ 1 more updateEnzo Biochem, Inc., Annual General Meeting, Jan 15, 2025Enzo Biochem, Inc., Annual General Meeting, Jan 15, 2025.New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 35% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Shareholders have been diluted in the past year (5.1% increase in shares outstanding). Market cap is less than US$100m (€55.3m market cap, or US$60.1m).お知らせ • Oct 30Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024The Board of Directors of Enzo Biochem, Inc. has declared a cash dividend of $0.10 per share on its common stock, payable on December 2, 2024, to the holders of record as of the close of business on November 15, 2024.Board Change • Sep 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Brad Radoff is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 16Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)Third quarter 2024 results: US$0.042 loss per share (improved from US$0.31 loss in 3Q 2023). Revenue: US$8.02m (down 50% from 3Q 2023). Net loss: US$2.13m (loss narrowed 86% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 14Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.23 loss in 2Q 2023)Second quarter 2024 results: US$0.017 loss per share (improved from US$0.23 loss in 2Q 2023). Revenue: US$8.55m (down 48% from 2Q 2023). Net loss: US$863.0k (loss narrowed 92% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 38 percentage points per year, which is a significant difference in performance.お知らせ • Feb 01+ 1 more updateEnzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive OfficerOn January 31, 2024, the board of directors of Enzo Biochem, Inc. appointed Kara Cannon to serve as the Chief Executive Officer of the Company, in each case, until her successor is duly elected and qualified. Ms. Cannon previously served as the Company’s interim Chief Executive Officer since her appointment to such position on September 5, 2023, as disclosed in a Current Report on Form 8-K filed by the Company on September 7, 2023. Prior to that, Ms. Cannon was the Company’s Chief Operating Officer; she has been employed with the Company since 2011.お知らせ • Dec 23Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024, at 09:00 US Eastern Standard Time.お知らせ • Nov 01Enzo Biochem, Inc. announced delayed annual 10-K filingOn 10/31/2023, Enzo Biochem, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Nov 01High number of new directorsChairperson of the Board Steven Pully was the last director to join the board, commencing their role in 2023.お知らせ • Oct 31Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of DirectorsEnzo Biochem, Inc. announced that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. Mr. Pully is currently a partner of Speyside Partners, an investment banking firm that he co-founded in May 2017. He also serves on the boards or in executive positions for various companies, including publicly-traded RumbleOn, Inc., where he serves as the Executive Chairman. Mr. Pully’s board service has spanned multiple industries, including airlines, amusement parks, energy and power, manufacturing, power sports, retail, restaurants, and technology. His board service has included multiple positions as chairman or lead director of the board, and also multiple chairmanships of audit, compensation, nominating and governance, and special committees. Previously, Mr. Pully served as General Counsel and as a Partner of the investment firm, Carlson Capital, L.P. from 2008 to 2014, as Managing Director in the investment banking division of Bank of America and as a Senior Managing Director in the investment banking department of Bear Stearns & Company. Mr. Pully is also an attorney and CPA, he is a Chartered Financial Analyst, and he also holds various FINRA licenses.Board Change • Sep 10High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 07Enzo Biochem, Inc. Announces CEO ChangesEnzo Biochem, Inc. announced that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of thousands of high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo Biochem, Inc.’s Life Science division supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry.お知らせ • May 10Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027Enzo Biochem, Inc. provided earnings guidance for the years 2023, 2024, 2025, 2026 and 2027. For the year 2023, the company expects revenue of $52.0 million and LBIT of $15.8 million. For the year 2024, the company expects revenue of $70.4 million and LBIT of $14.4 million. For the year 2025, the company expects revenue of $80.9 million and LBIT of $11.5 million. For the year 2026, the company expects revenue of $94.4 million and LBIT of $6.8 million. For the year 2027, the company expects revenue of $112.7 million and EBIT of $2.6 million.Reported Earnings • Mar 21Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)Second quarter 2023 results: US$0.23 loss per share (further deteriorated from US$0.055 loss in 2Q 2022). Revenue: US$16.3m (down 52% from 2Q 2022). Net loss: US$11.3m (loss widened 326% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Reported Earnings • Dec 14First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)First quarter 2023 results: US$0.22 loss per share (further deteriorated from US$0.048 loss in 1Q 2022). Revenue: US$18.3m (down 31% from 1Q 2022). Net loss: US$10.6m (loss widened 359% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.お知らせ • Dec 08Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022Enzo Biochem, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on Dec 12, 2022Recent Insider Transactions • Nov 29CEO & Director recently bought €190k worth of stockOn the 23rd of November, Hamid Erfanian bought around 100k shares on-market at roughly €1.90 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €4.8m. Hamid has been a buyer over the last 12 months, purchasing a net total of €200k worth in shares.Recent Insider Transactions • Nov 25Insider recently bought €4.8m worth of stockOn the 18th of November, James Wolf bought around 662k shares on-market at roughly €7.24 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €7.6m more in shares than they have sold in the last 12 months.Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 09Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023.お知らせ • Oct 21+ 1 more updateEnzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022On October 15, 2022, Enzo Biochem, Inc. (the Company) received written notice from David Bench that he was tendering his resignation as Senior Vice President, Treasurer and Corporate Secretary of the Company, effective November 14, 2022. His decision to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices (financial or otherwise). The Company has accepted Mr. Bench’s resignation, effective as of November 14, 2022.Reported Earnings • Oct 16Full year 2022 earnings released: US$0.38 loss per share (vs US$0.16 profit in FY 2021)Full year 2022 results: US$0.38 loss per share (down from US$0.16 profit in FY 2021). Revenue: US$107.1m (down 9.1% from FY 2021). Net loss: US$18.3m (down 332% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Oct 11Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022Enzo Biochem, Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Oct 14, 2022お知らせ • Sep 27Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2Enzo Biochem, Inc. announced the launch of the AMPIVIEW(TM) line, a breakthrough RNA gene expression platform powered by Enzo's LoopRNA(TM) in situ hybridization technology. The AMPIVIEW(TM) platform with its first products for HPV detection and analysis significantly expands Enzo's position in the oncology market and paves the way for expansion into the growing spatial biology space. Enzo's AMPIVIEW(TM) RNA products combine the precision of targeted, sequence-specific probes with the superior sensitivity of its novel LoopRNA(TM) ISH technology. This innovative design enables sensitive and specific detection of target genes in tissue or cell samples while preserving the morphology. The study of single cells within their native tissue environment, known as spatial biology, helps scientists better characterize and understand disease. This spatial biology market is expected to reach $2.15B in 2030(1) with a compound annual growth rate (CAGR) of 13.6%. HPV testing is part of Enzo's focus on women's health and oncology and leverages the Company's long history in HPV detection while complementing the existing offering of Enzo's POLYVIEW(R) immunohistochemistry ("IHC") and PATHO-GENE(R) in situ hybridization ("ISH") detection platforms, an enhanced diagnostic detection system used by pathologists in reading tissue biopsies. Applying this powerful AMPIVIEW(TM) visualization technology to HPV analysis is a logical extension of Enzo's already broad portfolio of tissue analysis assays and reagents.お知らせ • Aug 12Enzo Biochem, Inc. to Launch Monkeypox Testing Services This WeekEnzo Biochem, Inc. announced that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week. Monkeypox is a rare, infectious viral disease that spreads by person-to-person transmission (through skin-to-skin contact, fomites, contact with body fluids, or lesion materials) and can lead to serious health consequences. The monkeypox virus (orthopoxvirus) belongs to the same family of viruses as the variola virus, the pathogen that causes smallpox. Monkeypox has been spreading globally in recent months, having infected more than 30,000 individuals worldwide. Approximately 9,500 cases of monkeypox have been diagnosed in the U.S., with many more cases likely unreported. Enzo is building on the Company’s decades of experience processing specimens for the detection of viral pathogens. The monkeypox test to be offered by Enzo is an FDA-cleared, PCR-based DNA assay developed by the United States Center for Disease Control and Prevention (CDC). Enzo is concurrently applying its technical expertise in molecular diagnostics to develop a next generation monkeypox (orthopoxvirus) testing option. Enzo expects to address issues with regards to broadening collection methods, accelerating test turnaround times, and providing improved analytical sensitivity, and specificity. In consultation with the CDC and the FDA, the Company plans to implement these enhanced test features. Enzo continues to meet the needs of clients in their efforts to provide comprehensive diagnostic testing solutions for emerging pathogens.お知らせ • Aug 04Enzo Biochem, Inc. Announces Executive ChangesEnzo Biochem, Inc. announced the addition of Matthew Kupferberg as the companys in-house General Counsel. Mr. Hamid Erfanian, Chief Executive Officer of Enzo, stated, We are excited to add someone of Matthews caliber to executive team. Mr. Kupferberg brings a plethora of experiences including leading transactional and legal activities for health and wellness companies and providing counsel regarding corporate governance issues. He has worked with payors, PBMs, providers and medical device manufacturers, assisting multi-billion-dollar corporations to negotiate and structure complex health care arrangements. Furthermore, he has led day-to-day strategic legal counsel and provided guidance on a range of compliance and regulatory matters. Matthew Kupferberg was most recently General Counsel, Chief Compliance Officer and Privacy Officer of Digital Medical Technologies, LLC (dba AdhereTech), a medication adherence technology company. His previous experience includes Health Delegates, LLC, RxEDO, Inc. and DaVita, Inc. At DaVita, he was Assistant General Counsel to DaVita Rx, DaVitas pharmacy subsidiary. He also served as Assistant General Counsel at Humana, Inc., a managed health care company that markets and administers health insurance. Earlier in his career Mr. Kupferberg worked at the law firms ArentFox Schiff LLP and McDermott, Will &Emery. He received his B.A. from Binghamton University (Phi Beta Kappa) and his J.D. from Boston College Law School. Mr. Kupferberg is licensed in the States of New York, New Jersey, and Massachusetts.Recent Insider Transactions • Jul 08Independent Director recently bought €258k worth of stockOn the 5th of July, Bradley Radoff bought around 120k shares on-market at roughly €2.15 per share. In the last 3 months, they made an even bigger purchase worth €262k. Insiders have collectively bought €6.1m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Jun 18Independent Director recently bought €262k worth of stockOn the 16th of June, Bradley Radoff bought around 125k shares on-market at roughly €2.10 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €5.9m more in shares than they have sold in the last 12 months.Reported Earnings • Jun 11Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)Third quarter 2022 results: US$0.10 loss per share (down from US$0.041 profit in 3Q 2021). Revenue: US$26.2m (down 20% from 3Q 2021). Net loss: US$4.85m (down 342% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Jun 03Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022Enzo Biochem, Inc. announced that they will report Q3, 2022 results After-Market on Jun 09, 2022Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 20Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic TestEnzo Biochem, Inc. announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE(R) HPV test. The AMPIPROBE(R) HPV test is Enzo's PCR-based test designed to detect 14 high-risk human papillomavirus (HPV) variants. HPV testing is part of Enzo's focus on women's health and oncology and leverages the Company's long history in HPV detection. Almost all cervical cancers are linked to infection with high-risk HPV, an extremely common virus transmitted through sexual contact. With early detection and proper management, cervical cancer can often be treated successfully. The U.S. Centers for Disease Control and Prevention estimates that about 79 million Americans are currently infected with HPV, with over 14 million becoming newly infected each year. In addition to Enzo's HPV test, the Enzo Clinical Labs team remains committed to improving women's health by offering comprehensive and reliable testing solutions in other areas. Currently, its AMPIPROBE Women's Health Panel is a multiplex nucleic acid amplification test that can detect 16 common targets for sexually transmitted diseases and pathogens, including candida, chlamydia trachomatis, Neisseria gonorrhoeae, trichomonas vaginalis, ureaplasma, mycoplasma and bacterial vaginosis (BV) on a single APTIMA(R) swab.お知らせ • Apr 04Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022, at 09:00 US Eastern Standard Time. Agenda: To change the purpose of the company to carry on any lawful business; to declassify the Board; to remove Article 7 regarding the Company's first accounting period for 1976; to change the required shareholder vote for approval of mergers, asset sales, and dissolution from two-thirds vote to majority vote; to change the required shareholder vote for amendments to the Certificate of Incorporation to a majority vote; and to change the required vote for amendments to the Company's Amended and Restated By-Laws to either majority board approval or majority shareholder approval.お知らせ • Mar 29Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management PositionsEnzo Biochem, Inc. announced two key appointments to its new management structure. The Company announced Kara Cannon has been named Chief Operating Officer from her previous role as Chief Commercial Officer and David Bench, current Chief Financial Officer, has been named to the additional roles of Senior Vice President, Treasurer, and Corporate Secretary, effective immediately. David Bench has been employed with the Company since 2019. Mr. Bench was previously Chief Financial Officer of ELLKAY, LLC. Mr. Bench has served as President of DBC Group, LLC. Kara Cannon has been with the Company for over a decade having joined in 2011 and has been responsible for strategic and tactical marketing, sales, manufacturing and general management of operations. Ms. Cannon previously held executive positions at Pall Corporation. She has also held marketing and technical positions at Dynal Biotech.Reported Earnings • Mar 16Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.055 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$34.0m (up 8.2% from 2Q 2021). Net loss: US$2.66m (down 215% from profit in 2Q 2021). Revenue exceeded analyst estimates by 1.8%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 10Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022Barry Weiner has notified Enzo Biochem, Inc. that he has resigned as president of the company. The company has accepted Mr. Weiner's resignation effective April 19, 2022.Board Change • Feb 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder, Independent Outside Director & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 07Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Co-Founder, Chairman, Chief Scientific Officer & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. Lead Independent Director Mary Tagliaferri was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Recent Insider Transactions • Dec 29Insider recently bought €2.2m worth of stockOn the 21st of December, Bradley Radoff bought around 683k shares on-market at roughly €3.23 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €5.7m more in shares than they have sold in the last 12 months.Reported Earnings • Dec 16First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2022 results: US$0.048 loss per share (down from US$0.006 profit in 1Q 2021). Revenue: US$26.5m (down 7.5% from 1Q 2021). Net loss: US$2.32m (down US$2.62m from profit in 1Q 2021). Revenue exceeded analyst estimates by 1.8%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Oct 24Insider recently bought €1.3m worth of stockOn the 21st of October, Bradley Radoff bought around 415k shares on-market at roughly €3.09 per share. In the last 3 months, they made an even bigger purchase worth €2.1m. Insiders have collectively bought €3.5m more in shares than they have sold in the last 12 months.Valuation Update With 7 Day Price Move • Oct 21Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €2.76, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 23x in the Healthcare industry in Germany. Total loss to shareholders of 1.4% over the past three years.Reported Earnings • Oct 13Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$117.7m (up 55% from FY 2020). Net income: US$7.88m (up US$36.4m from FY 2020). Profit margin: 6.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Oct 07Insider recently bought €2.1m worth of stockOn the 5th of October, Bradley Radoff bought around 721k shares on-market at roughly €2.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €2.2m more in shares than they have sold in the last 12 months.お知らせ • Jun 28+ 4 more updatesEnzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value IndexEnzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value IndexReported Earnings • Jun 12Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$32.8m (up 94% from 3Q 2020). Net income: US$2.01m (up US$11.9m from 3Q 2020). Profit margin: 6.1% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 21Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a DirectorEnzo Biochem, Inc.'s Board of Directors accepted the recommendation of its Nominating/Governance Committee to reject Dr. Elazar Rabbani’s previous tender of resignation as a Director pursuant to the Company’s By Laws. The basis for such decision, which was made after careful deliberation and consideration, included among other factors, the understanding of Dr. Rabbani’s perceived value in facilitating the smooth transition of the Company’s leadership plans and Dr. Rabbani’s historical knowledge of the Company’s business and industry.Reported Earnings • Mar 17Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$31.5m (up 62% from 2Q 2020). Net income: US$2.30m (up US$9.99m from 2Q 2020). Profit margin: 7.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Mar 16Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEOEnzo Biochem, Inc. announced that after years of dedicated service, Dr. Elazar Rabbani, Founder and CEO, will remain a Director of the company and will step down as CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board. To fully capitalize on the potential of Enzo’s business model, the Company and the Board of Directors have retained the global search firm Korn Ferry to conduct the CEO search.お知らせ • Mar 04Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 VariantsEnzo Biochem, Inc. announced results of an analysis showing that tests processed on the company’s proprietary GENFLEX™ molecular diagnostic platform are successfully able to detect the presence of currently known variants of COVID-19. While the company’s PCR testing does not distinguish between different variants, positive samples can be further analyzed for variant identification. Rapid antigen tests currently available in the marketplace do not have this capability. On February 22, 2021, the US Food and Drug Administration issued new guidance for SARS-CoV-2 test developers to evaluate the potential impact of viral mutations on currently available diagnostic tests. In the guidance, the agency recommended molecular diagnostic test developers design their tests to minimize the impact of viral mutations on test performance, routinely monitor for viral mutations that may impact test performance, and clearly convey any test limitations in the test's labeling. Enzo’s GENFLEX™ Molecular Test has been shown to meet this standard. Enzo also recently published a new white paper analysis highlighting the key failures in the U.S. Diagnostics Sector’s response to the COVID-19 pandemic including challenges in development and delivery of accurate testing options, lack of scalability to meet demand, confusion about testing options and other areas. The paper, titled “COVID-19 Related Challenges in the U.S. Diagnostic Sector and Enzo’s Distinctive Response”, also outlines recommendations for broad structural changes to the diagnostics sector in the U.S. to position diagnostic companies and laboratories to better respond to global pandemics in the future. The paper highlights several structural inadequacies that negatively affected the ability of the U.S. healthcare system to respond to the COVID-19 pandemic and identifies a range of best practices for the diagnostics sector that can improve the nation’s healthcare infrastructure and ability to respond to global health crises. The study also offers perspectives on the emerging issue of testing variants of SARS-CoV-2, which is positioned as a potentially significant challenge that could lead to a new peak in infections. The study outlines the use of technology to probe the nucleocapsid (N) gene targets, presenting the potential to rapidly detect variants including B.1.1.7 (United Kingdom), P.1 (Brazil), and B.1.351 (South Africa) circulating worldwide. The ability to detect the incidence and spread of variants will play a central role in response to COVID-19 infection in the months ahead even as access to vaccines expands.お知らせ • Mar 02Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021Enzo Biochem, Inc. announced that they will report Q2, 2021 results After-Market on Mar 15, 2021Is New 90 Day High Low • Feb 06New 90-day high: €2.76The company is up 59% from its price of €1.74 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period.お知らせ • Feb 04Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target SclerostinEnzo Biochem, Inc. announced the recent issuance of U.S. Patent No. 10,899,827 entitled Antibodies Specific for Sulfation Sites of Sclerostin. The new patent is a member of a broader U.S. and international patent family that also includes issued patents and pending patent applications for therapies including monoclonal antibodies and small synthetic peptides used to inhibit sclerostin in the treatment of bone disorders such as osteoporosis. Enzo’s patent focuses on polyclonal antibodies that bind a specific region of human sclerostin, a protein that is a negative regulator of bone growth. Sclerostin is produced in osteocytes, a type of bone cell, and is known to inhibit bone formation. The maintenance of bone over time requires a balance between the formation of new bone tissue and the breakdown and removal of old bone tissue. Osteoporosis is a medical condition that causes bones to become brittle, making them more susceptible to fractures. According to the International Osteoporosis Foundation, about 200 million people worldwide and 53 million people in the U.S. suffer from osteoporosis disorder and approximately 50% of women and 25% of men age 50 and older will break a bone due to osteoporosis. The global market for drugs to treat osteoporosis is expected to grow at a compounded annual growth rate of 4.4%, reaching $10.9 billion by 2026.お知らせ • Jan 22Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession CommitteesEnzo Biochem, Inc. announced that the Enzo Board of Directors has formed two new committees to support strategy related to targeting and execution of new business opportunities and development and support for new members of the leadership team within the Company. The newly formed Corporate Development Committee is led by newly elected board member Ian Walters, MD & MBA, and independent board member Dov Perlysky, MBA. They will evaluate and provide guidance to the Company on acquisition, divestiture, and partnership opportunities within the life sciences industry. Both directors will work to support Enzo’s internal M&A team in identifying and assessing business development opportunities. The Company’s Board of Directors has ninety days from the election results certification to make a decision with respect to Dr. Rabbani’s offered resignation from his position as Chairman of the Board.お知らせ • Jan 05Enzo Biochem Receives FDA Emergency Use Authorization for Testing Pooled Samples on Three Platforms Including company’s GENFLEX™ Proprietary System for Detection of Coronavirus SARS-Cov-2Enzo Biochem, Inc. announced that it has received an expansion of its Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) authorizing the use of pooled samples containing up to five individual swab specimens with the Company’s AMPIPROBE® SARS-Cov-2 Test System utilizing tests on three different platforms including Enzo’s proprietary GENFLEX™ automated high-throughput platform. Pooling samples involves qualitative detection of nucleic acid from SARS-CoV-2 in up to five individual upper respiratory swab specimens collected in separate vials containing transport media from individuals that healthcare providers consider to be suspected of COVID-19 infection. Samples can include nasal, mid-turbinate, nasopharyngeal, or oropharyngeal swabs. The now authorized “pooled” approach significantly increases the number of individuals who can be tested with available testing resources. In its letter of authorization dated December 30, 2020, the FDA stated that the AMPIPROBE® SARS-Cov-2 Test System is authorized under EUA and the “product described in the Scope of Authorization of this letter (Section II) meets the criteria set forth in Section 564(c) of the (Federal, Food, Drug, and Cosmetic) Act concerning safety and potential effectiveness.Is New 90 Day High Low • Jan 05New 90-day high: €2.30The company is up 22% from its price of €1.89 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day high: €2.10The company is up 7.0% from its price of €1.96 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period.Reported Earnings • Dec 11First quarter 2021 earnings released: EPS US$0.006The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$28.7m (up 42% from 1Q 2020). Net income: US$299.0k (up US$7.95m from 1Q 2020). Profit margin: 1.0% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.お知らせ • Dec 03Enzo Biochem, Inc. to Report Q1, 2021 Results on Dec 09, 2020Enzo Biochem, Inc. announced that they will report Q1, 2021 results at 5:00 PM, Eastern Standard Time on Dec 09, 2020お知らせ • Nov 26Enzo Biochem, Inc. Announces Appointment of Ian B. Walters to Board of DirectorsEnzo Biochem, Inc. announced that Ian B. Walters, MD, has been appointed to the Company’s Board of Directors effective immediately. Dr. Walters is an experienced entrepreneur and drug developer with leadership in the development of over 30 drugs in multiple therapeutic areas involving diverse technologies, leading to five new oncology drug approvals. His previous positions include Executive Director of Global Oncology Clinical Research and Business Development for Bristol-Myers Squibb, and Medical Director at Millennium Pharmaceuticals. Dr. Walters currently is CEO and Director of Portage Biotech.お知らせ • Nov 19Enzo Biochem, Inc. Appoints Mary Tagliaferri to Its Board of DirectorsEnzo Biochem, Inc. announced that Mary Tagliaferri, MD, has been appointed to the company’s Board of Directors effective immediately. Dr. Tagliaferri is currently Executive Clinical Fellow and Senior Vice President and she was previously Chief Medical Officer at Nektar Therapeutics. Previously, she served as Chief Medical Officer and Chief Regulatory Officer for Kanglaite-USA and was Co-Founder, President and Board Member of Bionovo, Inc.お知らせ • Nov 18Enzo Biochem, Inc. Announces Resignation of Peter J. Clemens, IV from the Board of Directors as Class II DirectorOn November 9, 2020, Peter J. Clemens, IV resigned from the Board of Directors (the Board") of Enzo Biochem, Inc. (the Company") as a Class II director, effective immediately.お知らせ • Nov 06Enzo Biochem, Inc. Launches Portable Microplate Reader for Use with its Elisa and Assay Kits to Simplify Laboratory WorkflowEnzo Biochem, Inc. announced the commercial launch of a small portable microplate reader for use with the company’s immunoassays and, ultimately, molecular diagnostics, providing new opportunities in point-of-care medicine. This affordable device enables Enzo to offer a complete solution to academic, CRO, and industrial customers. Enzo is the provider of over 17,000 ELISA (enzyme-linked immunosorbent assay) and assay kits, including hundreds of highly sensitive ELISAs it manufactures. The advanced design and technology of Enzo’s compact microplate reader makes it possible to deliver precise and accurate results. Together with Enzo’s proprietary software, the device is an option for a wide variety of applications based on the miniaturization of Enzo’s assays. These tests include metabolites, hormones (e.g. pregnancy), proteins (e.g. inflammatory cytokines) and protein characterization. With support from an instrument manufacturing company, the Enzo portable reader enables lab work to be executed outside of traditional research facilities (that rely on shared instrumentation). Now, researchers and lab professionals can have a dedicated, personal device to fit their space and needs with convenience and accessibility not previously available. The handheld instrument is about one-tenth the size of the average benchtop plate reader, allowing it to fit into any laboratory setting and saving bench space while providing new levels of flexibility and portability that can be extended to point-of-care facilities to allow physicians to provide molecular testing including assays for viral detection and sexually transmitted diseases. The compact solid-state technology enables utilization of this instrument in new locations. With this technology, point-of-care testing can move from centralized, complex clinical labs closer to patient care. It simplifies testing procedures and opens up the opportunity to shift testing out of the hands of licensed medical technicians to healthcare professionals operating nearer to patients or, in some instances, even to patients themselves.お知らせ • Oct 29Enzo Biochem Launches GoTestMeNow Online Platform for Consumers to Directly Order COVID-19 Laboratory TestsEnzo Biochem, Inc. announced that it has launched GoTestMeNow, a new online platform that enables consumers to directly order physician-authorized laboratory testing. GoTestMeNow can be used to access necessary medical tests without the need for a doctor’s office visit. Specimen collection and testing is accomplished through a network of patient service centers in the New York/New Jersey metro area. Consumers can obtain results through a secure online portal. The GoTestMeNow direct-to-consumer laboratory testing capability will initially support access to COVID-19 molecular and antibody testing, and the platform will be expanded to offer access to a broad range of additional tests in the near future. The GoTestMeNow™ platform is designed to offer the highest levels of speed and convenience in helping consumers access laboratory testing services: Individuals order the desired test online. A licensed physician providing clinical oversight for GoTestMeNow™ services will be alerted for prompt review and authorization of the test. The platform facilitates all needs related to payment, including insurance coverage. Consumers can visit the testing location that is most convenient for their needs. Results are available to patients through a secure online portal.Is New 90 Day High Low • Oct 23New 90-day low: €1.66The company is down 20% from its price of €2.08 on 24 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 16% over the same period.Reported Earnings • Oct 15Full year earnings released - €0.60 loss per shareOver the last 12 months the company has reported total losses of US$28.5m, with earnings decreasing by US$31.0m from the prior year. Total revenue was US$76.0m over the last 12 months, down 6.3% from the prior year.お知らせ • Oct 07Enzo Biochem, Inc. to Report Q4, 2020 Results on Oct 13, 2020Enzo Biochem, Inc. announced that they will report Q4, 2020 results on Oct 13, 2020株主還元EZBDE Life SciencesDE 市場7D0%1.5%3.8%1Y-62.7%-9.6%3.9%株主還元を見る業界別リターン: EZB過去 1 年間で-9.6 % の収益を上げたGerman Life Sciences業界を下回りました。リターン対市場: EZBは、過去 1 年間で3.9 % のリターンを上げたGerman市場を下回りました。価格変動Is EZB's price volatile compared to industry and market?EZB volatilityEZB Average Weekly Movementn/aLife Sciences Industry Average Movement7.7%Market Average Movement5.6%10% most volatile stocks in DE Market12.5%10% least volatile stocks in DE Market2.7%安定した株価: EZBの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のEZBのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト1976131Kara Cannonwww.enzo.comライフサイエンス企業であるエンゾ・バイオケム社は、DNAから全細胞分析までの標識・検出技術を米国内外で展開している。同社が提供する標識、色素、抗体、ゲノムプローブ、イムノアッセイ、生化学物質、タンパク質は、創薬探索や医薬品開発プロセス開発において、関心のある生物学的標的を標識、検出、可視化するために使用される。同社独自の製品と技術は、細胞生物学、ゲノミクス、アッセイ、免疫組織化学、低分子化学など、トランスレーショナルリサーチや医薬品開発の分野で役割を果たしている。同社は技術のライセンス供与を行っている。学術研究者、臨床研究者、バイオテクノロジーおよび製薬会社、診断薬メーカーにサービスを提供している。エンゾ・バイオケム社は1976年に設立され、ニューヨーク州ファーミングデールに本社を置いている。もっと見るEnzo Biochem, Inc. 基礎のまとめEnzo Biochem の収益と売上を時価総額と比較するとどうか。EZB 基礎統計学時価総額€30.39m収益（TTM）-€6.67m売上高(TTM)€23.39m1.3xP/Sレシオ-4.6xPER（株価収益率EZB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計EZB 損益計算書（TTM）収益US$27.47m売上原価US$15.71m売上総利益US$11.77mその他の費用US$19.61m収益-US$7.84m直近の収益報告Apr 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.15グロス・マージン42.83%純利益率-28.54%有利子負債／自己資本比率0.5%EZB の長期的なパフォーマンスは？過去の実績と比較を見る配当金14.7%現在の配当利回り-67%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/07/28 16:13終値2025/04/30 00:00収益2025/04/30年間収益2024/07/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Enzo Biochem, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Bradley BerningCraig-Hallum Capital Group LLCJack WallaceSidoti & Company, LLC
お知らせ • Aug 29Enzo Biochem Appoints Jason Apter as Group CEOBattery Ventures announced the completion of its take-private of Enzo Biochem (Enzo). As part of this initiative, veteran life-science executive Jason Apter has joined Enzo as group CEO. Apter previously served as CEO of Sannova Analytical, an organization offering bioanalytical and analytical testing services to pharmaceutical and biotech companies. He also held senior leadership roles at MilliporeSigma and Johnson Matthey. Apter will be supported on Enzo’s board of directors by Battery’s Rosner, Feldman and Alan Hirzel, the former CEO of biological-reagents company Abcam.
お知らせ • Aug 21Enzo Biochem, Inc. Files Form 15Enzo Biochem, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share.
お知らせ • Aug 20Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB).Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. As of August 19 2025, the transaction was approved by target shareholders. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P. Equiniti Trust Company, LLC acted as Transfer agent to Enzo Biochem. Kingsdale Advisors LP acted as a proxy solicitor to Enzo Biochem. Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB) on August 20, 2025.
お知らせ • Jun 26Enzo Biochem to Delist After Merger CompletionEnzo Biochem announced that on June 23, following the market close, it entered into an Agreement and Plan of Merger to be acquired by Battery Ventures, a technology-focused investment firm, through its newly formed entity Bethpage Parent. Under the terms of the merger agreement, Battery will acquire Enzo for 70c per share in cash, representing a total consideration of approximately $37 million. Following the closing of the transaction, the company will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges.
お知らせ • Jun 25Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million.Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P.
お知らせ • Jan 16Enzo Biochem Receives Non-Compliance Letter from NYSEOn January 8, 2025 Enzo Biochem, Inc. (the Company") received a letter from the New York Stock Exchange (the NYSE") notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company's 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Common Stock (the Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock from the NYSE. With regards to the average closing stock price deficiency, the Company can regain compliance at any time within the six-month period following receipt of the NYSE's non-compliance notice if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE's listing rules, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the following 30 consecutive trading days. The Company will notify the NYSE by January 23, 2025, that it intends to submit a plan by February 21, 2025, to cure the market capitalization, stockholder's equity and average closing stock price deficiencies and to return to compliance with the NYSE's continued listing standards. The Company intends to consider all available alternatives to cure the deficiencies identified by the NYSE. The Common Stock will continue to be listed and trade on the NYSE, subject to the Company's ongoing compliance with the NYSE's other continued listing standards.
お知らせ • Aug 29Enzo Biochem Appoints Jason Apter as Group CEOBattery Ventures announced the completion of its take-private of Enzo Biochem (Enzo). As part of this initiative, veteran life-science executive Jason Apter has joined Enzo as group CEO. Apter previously served as CEO of Sannova Analytical, an organization offering bioanalytical and analytical testing services to pharmaceutical and biotech companies. He also held senior leadership roles at MilliporeSigma and Johnson Matthey. Apter will be supported on Enzo’s board of directors by Battery’s Rosner, Feldman and Alan Hirzel, the former CEO of biological-reagents company Abcam.
お知らせ • Aug 21Enzo Biochem, Inc. Files Form 15Enzo Biochem, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.01 per share.
お知らせ • Aug 20Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB).Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. As of August 19 2025, the transaction was approved by target shareholders. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P. Equiniti Trust Company, LLC acted as Transfer agent to Enzo Biochem. Kingsdale Advisors LP acted as a proxy solicitor to Enzo Biochem. Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P completed the acquisition of Enzo Biochem, Inc. (OTCPK:ENZB) on August 20, 2025.
お知らせ • Jun 26Enzo Biochem to Delist After Merger CompletionEnzo Biochem announced that on June 23, following the market close, it entered into an Agreement and Plan of Merger to be acquired by Battery Ventures, a technology-focused investment firm, through its newly formed entity Bethpage Parent. Under the terms of the merger agreement, Battery will acquire Enzo for 70c per share in cash, representing a total consideration of approximately $37 million. Following the closing of the transaction, the company will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges.
お知らせ • Jun 25Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million.Battery Ventures XIV-EF, L.P., Battery Ventures XIV, L.P. and Battery Investment Partners XIV, L.P managed by Battery Ventures L.P agreed to acquire Enzo Biochem, Inc. (OTCPK:ENZB) for $37.1 million on June 23, 2025. Battery will acquire Enzo for $0.70 per share in cash, representing a total consideration of approximately $37 million. In case of termination of transaction, Battery Ventures L.P will pay a termination fee of $1 million and Enzo will pay a termination fee of $2.5 million. The special committee of the Enzo Board of Directors (the “Strategic Committee”) to conduct a comprehensive review of value-maximizing alternatives. The transaction has been unanimously approved by the board of directors of Battery and Enzo and is subject to customary closing conditions, including shareholder approval. Subject to the satisfaction of these conditions, the transaction is expected to close in the third quarter of the calendar year. Following the closing of the transaction, Enzo will be privately held, and shares of OTCQX: ENZB will no longer be listed on public market exchanges. BroadOak Capital Partners, LLC acted as financial advisor and fairness opinion provider for Enzo Biochem, Inc. Adam W. Finerman of Baker & Hostetler LLP acted as legal advisor for Enzo Biochem, Inc. Alfred Browne and Izzy Lubarsky of Cooley LLP acted as legal advisor for Battery Ventures L.P.
お知らせ • Jan 16Enzo Biochem Receives Non-Compliance Letter from NYSEOn January 8, 2025 Enzo Biochem, Inc. (the Company") received a letter from the New York Stock Exchange (the NYSE") notifying the Company that it is not in compliance with (i) Section 802.01B of the NYSE Listed Company Manual because as of January 7, 2025, the Company's 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's Common Stock (the Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and stockholder's equity deficiencies and a period of six months to cure the average closing stock price deficiency. The notice does not result in the immediate delisting of the Common Stock from the NYSE. With regards to the average closing stock price deficiency, the Company can regain compliance at any time within the six-month period following receipt of the NYSE's non-compliance notice if, on the last trading day of any calendar month during the cure period, the Company has (i) a closing share price of at least $1.00 and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. Under the NYSE's listing rules, the price condition will be deemed cured if the price promptly exceeds $1.00 per share and the price remains above that level for at least the following 30 consecutive trading days. The Company will notify the NYSE by January 23, 2025, that it intends to submit a plan by February 21, 2025, to cure the market capitalization, stockholder's equity and average closing stock price deficiencies and to return to compliance with the NYSE's continued listing standards. The Company intends to consider all available alternatives to cure the deficiencies identified by the NYSE. The Common Stock will continue to be listed and trade on the NYSE, subject to the Company's ongoing compliance with the NYSE's other continued listing standards.
お知らせ • Nov 28+ 1 more updateEnzo Biochem, Inc., Annual General Meeting, Jan 15, 2025Enzo Biochem, Inc., Annual General Meeting, Jan 15, 2025.
New Risk • Nov 01New minor risk - Dividend sustainabilityThe company has a short dividend paying track record. Less than a year of continuous dividend payments. Dividend yield: 35% This is considered a minor risk. For dividend focussed investors, companies that have not established a long-term track record of consistently maintaining or growing dividends are less attractive than those companies that have a long track record. Those that have a long track record have proven their underlying business is stable enough to consistently maintain or grow the dividend and that the company considers maintaining the dividend to be one of its priorities. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Short dividend paying track record (less than a year of continuous dividend payments). Shareholders have been diluted in the past year (5.1% increase in shares outstanding). Market cap is less than US$100m (€55.3m market cap, or US$60.1m).
お知らせ • Oct 30Enzo Biochem, Inc. Announces Cash Dividend, Payable on December 2, 2024The Board of Directors of Enzo Biochem, Inc. has declared a cash dividend of $0.10 per share on its common stock, payable on December 2, 2024, to the holders of record as of the close of business on November 15, 2024.
Board Change • Sep 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Brad Radoff is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 16Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)Third quarter 2024 results: US$0.042 loss per share (improved from US$0.31 loss in 3Q 2023). Revenue: US$8.02m (down 50% from 3Q 2023). Net loss: US$2.13m (loss narrowed 86% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 14Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.23 loss in 2Q 2023)Second quarter 2024 results: US$0.017 loss per share (improved from US$0.23 loss in 2Q 2023). Revenue: US$8.55m (down 48% from 2Q 2023). Net loss: US$863.0k (loss narrowed 92% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 38 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 01+ 1 more updateEnzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive OfficerOn January 31, 2024, the board of directors of Enzo Biochem, Inc. appointed Kara Cannon to serve as the Chief Executive Officer of the Company, in each case, until her successor is duly elected and qualified. Ms. Cannon previously served as the Company’s interim Chief Executive Officer since her appointment to such position on September 5, 2023, as disclosed in a Current Report on Form 8-K filed by the Company on September 7, 2023. Prior to that, Ms. Cannon was the Company’s Chief Operating Officer; she has been employed with the Company since 2011.
お知らせ • Dec 23Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024, at 09:00 US Eastern Standard Time.
お知らせ • Nov 01Enzo Biochem, Inc. announced delayed annual 10-K filingOn 10/31/2023, Enzo Biochem, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Nov 01High number of new directorsChairperson of the Board Steven Pully was the last director to join the board, commencing their role in 2023.
お知らせ • Oct 31Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of DirectorsEnzo Biochem, Inc. announced that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well. Mr. Pully is currently a partner of Speyside Partners, an investment banking firm that he co-founded in May 2017. He also serves on the boards or in executive positions for various companies, including publicly-traded RumbleOn, Inc., where he serves as the Executive Chairman. Mr. Pully’s board service has spanned multiple industries, including airlines, amusement parks, energy and power, manufacturing, power sports, retail, restaurants, and technology. His board service has included multiple positions as chairman or lead director of the board, and also multiple chairmanships of audit, compensation, nominating and governance, and special committees. Previously, Mr. Pully served as General Counsel and as a Partner of the investment firm, Carlson Capital, L.P. from 2008 to 2014, as Managing Director in the investment banking division of Bank of America and as a Senior Managing Director in the investment banking department of Bear Stearns & Company. Mr. Pully is also an attorney and CPA, he is a Chartered Financial Analyst, and he also holds various FINRA licenses.
Board Change • Sep 10High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 07Enzo Biochem, Inc. Announces CEO ChangesEnzo Biochem, Inc. announced that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO. For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of thousands of high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo Biochem, Inc.’s Life Science division supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry.
お知らせ • May 10Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027Enzo Biochem, Inc. provided earnings guidance for the years 2023, 2024, 2025, 2026 and 2027. For the year 2023, the company expects revenue of $52.0 million and LBIT of $15.8 million. For the year 2024, the company expects revenue of $70.4 million and LBIT of $14.4 million. For the year 2025, the company expects revenue of $80.9 million and LBIT of $11.5 million. For the year 2026, the company expects revenue of $94.4 million and LBIT of $6.8 million. For the year 2027, the company expects revenue of $112.7 million and EBIT of $2.6 million.
Reported Earnings • Mar 21Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)Second quarter 2023 results: US$0.23 loss per share (further deteriorated from US$0.055 loss in 2Q 2022). Revenue: US$16.3m (down 52% from 2Q 2022). Net loss: US$11.3m (loss widened 326% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Reported Earnings • Dec 14First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)First quarter 2023 results: US$0.22 loss per share (further deteriorated from US$0.048 loss in 1Q 2022). Revenue: US$18.3m (down 31% from 1Q 2022). Net loss: US$10.6m (loss widened 359% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings.
お知らせ • Dec 08Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022Enzo Biochem, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on Dec 12, 2022
Recent Insider Transactions • Nov 29CEO & Director recently bought €190k worth of stockOn the 23rd of November, Hamid Erfanian bought around 100k shares on-market at roughly €1.90 per share. This transaction amounted to 36% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €4.8m. Hamid has been a buyer over the last 12 months, purchasing a net total of €200k worth in shares.
Recent Insider Transactions • Nov 25Insider recently bought €4.8m worth of stockOn the 18th of November, James Wolf bought around 662k shares on-market at roughly €7.24 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €7.6m more in shares than they have sold in the last 12 months.
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 09Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023.
お知らせ • Oct 21+ 1 more updateEnzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022On October 15, 2022, Enzo Biochem, Inc. (the Company) received written notice from David Bench that he was tendering his resignation as Senior Vice President, Treasurer and Corporate Secretary of the Company, effective November 14, 2022. His decision to resign was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices (financial or otherwise). The Company has accepted Mr. Bench’s resignation, effective as of November 14, 2022.
Reported Earnings • Oct 16Full year 2022 earnings released: US$0.38 loss per share (vs US$0.16 profit in FY 2021)Full year 2022 results: US$0.38 loss per share (down from US$0.16 profit in FY 2021). Revenue: US$107.1m (down 9.1% from FY 2021). Net loss: US$18.3m (down 332% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Oct 11Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022Enzo Biochem, Inc. announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Oct 14, 2022
お知らせ • Sep 27Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2Enzo Biochem, Inc. announced the launch of the AMPIVIEW(TM) line, a breakthrough RNA gene expression platform powered by Enzo's LoopRNA(TM) in situ hybridization technology. The AMPIVIEW(TM) platform with its first products for HPV detection and analysis significantly expands Enzo's position in the oncology market and paves the way for expansion into the growing spatial biology space. Enzo's AMPIVIEW(TM) RNA products combine the precision of targeted, sequence-specific probes with the superior sensitivity of its novel LoopRNA(TM) ISH technology. This innovative design enables sensitive and specific detection of target genes in tissue or cell samples while preserving the morphology. The study of single cells within their native tissue environment, known as spatial biology, helps scientists better characterize and understand disease. This spatial biology market is expected to reach $2.15B in 2030(1) with a compound annual growth rate (CAGR) of 13.6%. HPV testing is part of Enzo's focus on women's health and oncology and leverages the Company's long history in HPV detection while complementing the existing offering of Enzo's POLYVIEW(R) immunohistochemistry ("IHC") and PATHO-GENE(R) in situ hybridization ("ISH") detection platforms, an enhanced diagnostic detection system used by pathologists in reading tissue biopsies. Applying this powerful AMPIVIEW(TM) visualization technology to HPV analysis is a logical extension of Enzo's already broad portfolio of tissue analysis assays and reagents.
お知らせ • Aug 12Enzo Biochem, Inc. to Launch Monkeypox Testing Services This WeekEnzo Biochem, Inc. announced that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week. Monkeypox is a rare, infectious viral disease that spreads by person-to-person transmission (through skin-to-skin contact, fomites, contact with body fluids, or lesion materials) and can lead to serious health consequences. The monkeypox virus (orthopoxvirus) belongs to the same family of viruses as the variola virus, the pathogen that causes smallpox. Monkeypox has been spreading globally in recent months, having infected more than 30,000 individuals worldwide. Approximately 9,500 cases of monkeypox have been diagnosed in the U.S., with many more cases likely unreported. Enzo is building on the Company’s decades of experience processing specimens for the detection of viral pathogens. The monkeypox test to be offered by Enzo is an FDA-cleared, PCR-based DNA assay developed by the United States Center for Disease Control and Prevention (CDC). Enzo is concurrently applying its technical expertise in molecular diagnostics to develop a next generation monkeypox (orthopoxvirus) testing option. Enzo expects to address issues with regards to broadening collection methods, accelerating test turnaround times, and providing improved analytical sensitivity, and specificity. In consultation with the CDC and the FDA, the Company plans to implement these enhanced test features. Enzo continues to meet the needs of clients in their efforts to provide comprehensive diagnostic testing solutions for emerging pathogens.
お知らせ • Aug 04Enzo Biochem, Inc. Announces Executive ChangesEnzo Biochem, Inc. announced the addition of Matthew Kupferberg as the companys in-house General Counsel. Mr. Hamid Erfanian, Chief Executive Officer of Enzo, stated, We are excited to add someone of Matthews caliber to executive team. Mr. Kupferberg brings a plethora of experiences including leading transactional and legal activities for health and wellness companies and providing counsel regarding corporate governance issues. He has worked with payors, PBMs, providers and medical device manufacturers, assisting multi-billion-dollar corporations to negotiate and structure complex health care arrangements. Furthermore, he has led day-to-day strategic legal counsel and provided guidance on a range of compliance and regulatory matters. Matthew Kupferberg was most recently General Counsel, Chief Compliance Officer and Privacy Officer of Digital Medical Technologies, LLC (dba AdhereTech), a medication adherence technology company. His previous experience includes Health Delegates, LLC, RxEDO, Inc. and DaVita, Inc. At DaVita, he was Assistant General Counsel to DaVita Rx, DaVitas pharmacy subsidiary. He also served as Assistant General Counsel at Humana, Inc., a managed health care company that markets and administers health insurance. Earlier in his career Mr. Kupferberg worked at the law firms ArentFox Schiff LLP and McDermott, Will &Emery. He received his B.A. from Binghamton University (Phi Beta Kappa) and his J.D. from Boston College Law School. Mr. Kupferberg is licensed in the States of New York, New Jersey, and Massachusetts.
Recent Insider Transactions • Jul 08Independent Director recently bought €258k worth of stockOn the 5th of July, Bradley Radoff bought around 120k shares on-market at roughly €2.15 per share. In the last 3 months, they made an even bigger purchase worth €262k. Insiders have collectively bought €6.1m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Jun 18Independent Director recently bought €262k worth of stockOn the 16th of June, Bradley Radoff bought around 125k shares on-market at roughly €2.10 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €5.9m more in shares than they have sold in the last 12 months.
Reported Earnings • Jun 11Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)Third quarter 2022 results: US$0.10 loss per share (down from US$0.041 profit in 3Q 2021). Revenue: US$26.2m (down 20% from 3Q 2021). Net loss: US$4.85m (down 342% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Jun 03Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022Enzo Biochem, Inc. announced that they will report Q3, 2022 results After-Market on Jun 09, 2022
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder & Director Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 20Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic TestEnzo Biochem, Inc. announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE(R) HPV test. The AMPIPROBE(R) HPV test is Enzo's PCR-based test designed to detect 14 high-risk human papillomavirus (HPV) variants. HPV testing is part of Enzo's focus on women's health and oncology and leverages the Company's long history in HPV detection. Almost all cervical cancers are linked to infection with high-risk HPV, an extremely common virus transmitted through sexual contact. With early detection and proper management, cervical cancer can often be treated successfully. The U.S. Centers for Disease Control and Prevention estimates that about 79 million Americans are currently infected with HPV, with over 14 million becoming newly infected each year. In addition to Enzo's HPV test, the Enzo Clinical Labs team remains committed to improving women's health by offering comprehensive and reliable testing solutions in other areas. Currently, its AMPIPROBE Women's Health Panel is a multiplex nucleic acid amplification test that can detect 16 common targets for sexually transmitted diseases and pathogens, including candida, chlamydia trachomatis, Neisseria gonorrhoeae, trichomonas vaginalis, ureaplasma, mycoplasma and bacterial vaginosis (BV) on a single APTIMA(R) swab.
お知らせ • Apr 04Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022, at 09:00 US Eastern Standard Time. Agenda: To change the purpose of the company to carry on any lawful business; to declassify the Board; to remove Article 7 regarding the Company's first accounting period for 1976; to change the required shareholder vote for approval of mergers, asset sales, and dissolution from two-thirds vote to majority vote; to change the required shareholder vote for amendments to the Certificate of Incorporation to a majority vote; and to change the required vote for amendments to the Company's Amended and Restated By-Laws to either majority board approval or majority shareholder approval.
お知らせ • Mar 29Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management PositionsEnzo Biochem, Inc. announced two key appointments to its new management structure. The Company announced Kara Cannon has been named Chief Operating Officer from her previous role as Chief Commercial Officer and David Bench, current Chief Financial Officer, has been named to the additional roles of Senior Vice President, Treasurer, and Corporate Secretary, effective immediately. David Bench has been employed with the Company since 2019. Mr. Bench was previously Chief Financial Officer of ELLKAY, LLC. Mr. Bench has served as President of DBC Group, LLC. Kara Cannon has been with the Company for over a decade having joined in 2011 and has been responsible for strategic and tactical marketing, sales, manufacturing and general management of operations. Ms. Cannon previously held executive positions at Pall Corporation. She has also held marketing and technical positions at Dynal Biotech.
Reported Earnings • Mar 16Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatSecond quarter 2022 results: US$0.055 loss per share (down from US$0.048 profit in 2Q 2021). Revenue: US$34.0m (up 8.2% from 2Q 2021). Net loss: US$2.66m (down 215% from profit in 2Q 2021). Revenue exceeded analyst estimates by 1.8%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 10Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022Barry Weiner has notified Enzo Biochem, Inc. that he has resigned as president of the company. The company has accepted Mr. Weiner's resignation effective April 19, 2022.
Board Change • Feb 02High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder, Independent Outside Director & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 07Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Co-Founder, Chairman, Chief Scientific Officer & Secretary Elazar Rabbani is the most experienced director on the board, commencing their role in 1976. Lead Independent Director Mary Tagliaferri was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Recent Insider Transactions • Dec 29Insider recently bought €2.2m worth of stockOn the 21st of December, Bradley Radoff bought around 683k shares on-market at roughly €3.23 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €5.7m more in shares than they have sold in the last 12 months.
Reported Earnings • Dec 16First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst quarter 2022 results: US$0.048 loss per share (down from US$0.006 profit in 1Q 2021). Revenue: US$26.5m (down 7.5% from 1Q 2021). Net loss: US$2.32m (down US$2.62m from profit in 1Q 2021). Revenue exceeded analyst estimates by 1.8%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Oct 24Insider recently bought €1.3m worth of stockOn the 21st of October, Bradley Radoff bought around 415k shares on-market at roughly €3.09 per share. In the last 3 months, they made an even bigger purchase worth €2.1m. Insiders have collectively bought €3.5m more in shares than they have sold in the last 12 months.
Valuation Update With 7 Day Price Move • Oct 21Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €2.76, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 23x in the Healthcare industry in Germany. Total loss to shareholders of 1.4% over the past three years.
Reported Earnings • Oct 13Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$117.7m (up 55% from FY 2020). Net income: US$7.88m (up US$36.4m from FY 2020). Profit margin: 6.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Oct 07Insider recently bought €2.1m worth of stockOn the 5th of October, Bradley Radoff bought around 721k shares on-market at roughly €2.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €2.2m more in shares than they have sold in the last 12 months.
お知らせ • Jun 28+ 4 more updatesEnzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value IndexEnzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value Index
Reported Earnings • Jun 12Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$32.8m (up 94% from 3Q 2020). Net income: US$2.01m (up US$11.9m from 3Q 2020). Profit margin: 6.1% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 21Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a DirectorEnzo Biochem, Inc.'s Board of Directors accepted the recommendation of its Nominating/Governance Committee to reject Dr. Elazar Rabbani’s previous tender of resignation as a Director pursuant to the Company’s By Laws. The basis for such decision, which was made after careful deliberation and consideration, included among other factors, the understanding of Dr. Rabbani’s perceived value in facilitating the smooth transition of the Company’s leadership plans and Dr. Rabbani’s historical knowledge of the Company’s business and industry.
Reported Earnings • Mar 17Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$31.5m (up 62% from 2Q 2020). Net income: US$2.30m (up US$9.99m from 2Q 2020). Profit margin: 7.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 16Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEOEnzo Biochem, Inc. announced that after years of dedicated service, Dr. Elazar Rabbani, Founder and CEO, will remain a Director of the company and will step down as CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board. To fully capitalize on the potential of Enzo’s business model, the Company and the Board of Directors have retained the global search firm Korn Ferry to conduct the CEO search.
お知らせ • Mar 04Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 VariantsEnzo Biochem, Inc. announced results of an analysis showing that tests processed on the company’s proprietary GENFLEX™ molecular diagnostic platform are successfully able to detect the presence of currently known variants of COVID-19. While the company’s PCR testing does not distinguish between different variants, positive samples can be further analyzed for variant identification. Rapid antigen tests currently available in the marketplace do not have this capability. On February 22, 2021, the US Food and Drug Administration issued new guidance for SARS-CoV-2 test developers to evaluate the potential impact of viral mutations on currently available diagnostic tests. In the guidance, the agency recommended molecular diagnostic test developers design their tests to minimize the impact of viral mutations on test performance, routinely monitor for viral mutations that may impact test performance, and clearly convey any test limitations in the test's labeling. Enzo’s GENFLEX™ Molecular Test has been shown to meet this standard. Enzo also recently published a new white paper analysis highlighting the key failures in the U.S. Diagnostics Sector’s response to the COVID-19 pandemic including challenges in development and delivery of accurate testing options, lack of scalability to meet demand, confusion about testing options and other areas. The paper, titled “COVID-19 Related Challenges in the U.S. Diagnostic Sector and Enzo’s Distinctive Response”, also outlines recommendations for broad structural changes to the diagnostics sector in the U.S. to position diagnostic companies and laboratories to better respond to global pandemics in the future. The paper highlights several structural inadequacies that negatively affected the ability of the U.S. healthcare system to respond to the COVID-19 pandemic and identifies a range of best practices for the diagnostics sector that can improve the nation’s healthcare infrastructure and ability to respond to global health crises. The study also offers perspectives on the emerging issue of testing variants of SARS-CoV-2, which is positioned as a potentially significant challenge that could lead to a new peak in infections. The study outlines the use of technology to probe the nucleocapsid (N) gene targets, presenting the potential to rapidly detect variants including B.1.1.7 (United Kingdom), P.1 (Brazil), and B.1.351 (South Africa) circulating worldwide. The ability to detect the incidence and spread of variants will play a central role in response to COVID-19 infection in the months ahead even as access to vaccines expands.
お知らせ • Mar 02Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021Enzo Biochem, Inc. announced that they will report Q2, 2021 results After-Market on Mar 15, 2021
Is New 90 Day High Low • Feb 06New 90-day high: €2.76The company is up 59% from its price of €1.74 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period.
お知らせ • Feb 04Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target SclerostinEnzo Biochem, Inc. announced the recent issuance of U.S. Patent No. 10,899,827 entitled Antibodies Specific for Sulfation Sites of Sclerostin. The new patent is a member of a broader U.S. and international patent family that also includes issued patents and pending patent applications for therapies including monoclonal antibodies and small synthetic peptides used to inhibit sclerostin in the treatment of bone disorders such as osteoporosis. Enzo’s patent focuses on polyclonal antibodies that bind a specific region of human sclerostin, a protein that is a negative regulator of bone growth. Sclerostin is produced in osteocytes, a type of bone cell, and is known to inhibit bone formation. The maintenance of bone over time requires a balance between the formation of new bone tissue and the breakdown and removal of old bone tissue. Osteoporosis is a medical condition that causes bones to become brittle, making them more susceptible to fractures. According to the International Osteoporosis Foundation, about 200 million people worldwide and 53 million people in the U.S. suffer from osteoporosis disorder and approximately 50% of women and 25% of men age 50 and older will break a bone due to osteoporosis. The global market for drugs to treat osteoporosis is expected to grow at a compounded annual growth rate of 4.4%, reaching $10.9 billion by 2026.
お知らせ • Jan 22Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession CommitteesEnzo Biochem, Inc. announced that the Enzo Board of Directors has formed two new committees to support strategy related to targeting and execution of new business opportunities and development and support for new members of the leadership team within the Company. The newly formed Corporate Development Committee is led by newly elected board member Ian Walters, MD & MBA, and independent board member Dov Perlysky, MBA. They will evaluate and provide guidance to the Company on acquisition, divestiture, and partnership opportunities within the life sciences industry. Both directors will work to support Enzo’s internal M&A team in identifying and assessing business development opportunities. The Company’s Board of Directors has ninety days from the election results certification to make a decision with respect to Dr. Rabbani’s offered resignation from his position as Chairman of the Board.
お知らせ • Jan 05Enzo Biochem Receives FDA Emergency Use Authorization for Testing Pooled Samples on Three Platforms Including company’s GENFLEX™ Proprietary System for Detection of Coronavirus SARS-Cov-2Enzo Biochem, Inc. announced that it has received an expansion of its Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) authorizing the use of pooled samples containing up to five individual swab specimens with the Company’s AMPIPROBE® SARS-Cov-2 Test System utilizing tests on three different platforms including Enzo’s proprietary GENFLEX™ automated high-throughput platform. Pooling samples involves qualitative detection of nucleic acid from SARS-CoV-2 in up to five individual upper respiratory swab specimens collected in separate vials containing transport media from individuals that healthcare providers consider to be suspected of COVID-19 infection. Samples can include nasal, mid-turbinate, nasopharyngeal, or oropharyngeal swabs. The now authorized “pooled” approach significantly increases the number of individuals who can be tested with available testing resources. In its letter of authorization dated December 30, 2020, the FDA stated that the AMPIPROBE® SARS-Cov-2 Test System is authorized under EUA and the “product described in the Scope of Authorization of this letter (Section II) meets the criteria set forth in Section 564(c) of the (Federal, Food, Drug, and Cosmetic) Act concerning safety and potential effectiveness.
Is New 90 Day High Low • Jan 05New 90-day high: €2.30The company is up 22% from its price of €1.89 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day high: €2.10The company is up 7.0% from its price of €1.96 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period.
Reported Earnings • Dec 11First quarter 2021 earnings released: EPS US$0.006The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$28.7m (up 42% from 1Q 2020). Net income: US$299.0k (up US$7.95m from 1Q 2020). Profit margin: 1.0% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.
お知らせ • Dec 03Enzo Biochem, Inc. to Report Q1, 2021 Results on Dec 09, 2020Enzo Biochem, Inc. announced that they will report Q1, 2021 results at 5:00 PM, Eastern Standard Time on Dec 09, 2020
お知らせ • Nov 26Enzo Biochem, Inc. Announces Appointment of Ian B. Walters to Board of DirectorsEnzo Biochem, Inc. announced that Ian B. Walters, MD, has been appointed to the Company’s Board of Directors effective immediately. Dr. Walters is an experienced entrepreneur and drug developer with leadership in the development of over 30 drugs in multiple therapeutic areas involving diverse technologies, leading to five new oncology drug approvals. His previous positions include Executive Director of Global Oncology Clinical Research and Business Development for Bristol-Myers Squibb, and Medical Director at Millennium Pharmaceuticals. Dr. Walters currently is CEO and Director of Portage Biotech.
お知らせ • Nov 19Enzo Biochem, Inc. Appoints Mary Tagliaferri to Its Board of DirectorsEnzo Biochem, Inc. announced that Mary Tagliaferri, MD, has been appointed to the company’s Board of Directors effective immediately. Dr. Tagliaferri is currently Executive Clinical Fellow and Senior Vice President and she was previously Chief Medical Officer at Nektar Therapeutics. Previously, she served as Chief Medical Officer and Chief Regulatory Officer for Kanglaite-USA and was Co-Founder, President and Board Member of Bionovo, Inc.
お知らせ • Nov 18Enzo Biochem, Inc. Announces Resignation of Peter J. Clemens, IV from the Board of Directors as Class II DirectorOn November 9, 2020, Peter J. Clemens, IV resigned from the Board of Directors (the Board") of Enzo Biochem, Inc. (the Company") as a Class II director, effective immediately.
お知らせ • Nov 06Enzo Biochem, Inc. Launches Portable Microplate Reader for Use with its Elisa and Assay Kits to Simplify Laboratory WorkflowEnzo Biochem, Inc. announced the commercial launch of a small portable microplate reader for use with the company’s immunoassays and, ultimately, molecular diagnostics, providing new opportunities in point-of-care medicine. This affordable device enables Enzo to offer a complete solution to academic, CRO, and industrial customers. Enzo is the provider of over 17,000 ELISA (enzyme-linked immunosorbent assay) and assay kits, including hundreds of highly sensitive ELISAs it manufactures. The advanced design and technology of Enzo’s compact microplate reader makes it possible to deliver precise and accurate results. Together with Enzo’s proprietary software, the device is an option for a wide variety of applications based on the miniaturization of Enzo’s assays. These tests include metabolites, hormones (e.g. pregnancy), proteins (e.g. inflammatory cytokines) and protein characterization. With support from an instrument manufacturing company, the Enzo portable reader enables lab work to be executed outside of traditional research facilities (that rely on shared instrumentation). Now, researchers and lab professionals can have a dedicated, personal device to fit their space and needs with convenience and accessibility not previously available. The handheld instrument is about one-tenth the size of the average benchtop plate reader, allowing it to fit into any laboratory setting and saving bench space while providing new levels of flexibility and portability that can be extended to point-of-care facilities to allow physicians to provide molecular testing including assays for viral detection and sexually transmitted diseases. The compact solid-state technology enables utilization of this instrument in new locations. With this technology, point-of-care testing can move from centralized, complex clinical labs closer to patient care. It simplifies testing procedures and opens up the opportunity to shift testing out of the hands of licensed medical technicians to healthcare professionals operating nearer to patients or, in some instances, even to patients themselves.
お知らせ • Oct 29Enzo Biochem Launches GoTestMeNow Online Platform for Consumers to Directly Order COVID-19 Laboratory TestsEnzo Biochem, Inc. announced that it has launched GoTestMeNow, a new online platform that enables consumers to directly order physician-authorized laboratory testing. GoTestMeNow can be used to access necessary medical tests without the need for a doctor’s office visit. Specimen collection and testing is accomplished through a network of patient service centers in the New York/New Jersey metro area. Consumers can obtain results through a secure online portal. The GoTestMeNow direct-to-consumer laboratory testing capability will initially support access to COVID-19 molecular and antibody testing, and the platform will be expanded to offer access to a broad range of additional tests in the near future. The GoTestMeNow™ platform is designed to offer the highest levels of speed and convenience in helping consumers access laboratory testing services: Individuals order the desired test online. A licensed physician providing clinical oversight for GoTestMeNow™ services will be alerted for prompt review and authorization of the test. The platform facilitates all needs related to payment, including insurance coverage. Consumers can visit the testing location that is most convenient for their needs. Results are available to patients through a secure online portal.
Is New 90 Day High Low • Oct 23New 90-day low: €1.66The company is down 20% from its price of €2.08 on 24 July 2020. The German market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 16% over the same period.
Reported Earnings • Oct 15Full year earnings released - €0.60 loss per shareOver the last 12 months the company has reported total losses of US$28.5m, with earnings decreasing by US$31.0m from the prior year. Total revenue was US$76.0m over the last 12 months, down 6.3% from the prior year.
お知らせ • Oct 07Enzo Biochem, Inc. to Report Q4, 2020 Results on Oct 13, 2020Enzo Biochem, Inc. announced that they will report Q4, 2020 results on Oct 13, 2020
